Traductor

29 September 2010

AstraZeneca moves rheumatoid arthritis drug fostamatinib into late-stage development

AstraZeneca announced Wednesday enrolment of the first patient in a late-stage development programme for its experimental rheumatoid arthritis drug fostamatinib. The programme, which is called OSKIRA and is made up of three studies, is designed to investigate fostamatinib as a treatment for patients with an inadequate response to disease modifying anti-rheumatic drugs, including methotrexate. AstraZeneca plans to submits regulatory filings for the drug, which was licensed from Rigel Pharmaceuticals, in 2013.

Reference Articles
AstraZeneca initiates Phase III clinical development of fostamatinib for the treatment of rheumatoid arthritis - (AstraZeneca)
Astra starts final-stage trials of arthritis drug - (Forexpros)
Astra launches late-stage rheumatoid arthritis pill trials (free preview) - (The Wall Street Journal)

**Published in "First Word"

No comments:

Post a Comment

CONTACTO · Aviso Legal · Política de Privacidad · Política de Cookies

Copyright © Noticia de Salud